HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 08, August 2017 – Eye – the Window to your Soul       » Palm-Sized PCR Device for Rapid Real-Time Detection of Viruses       » Scientists Uncover New Mechanism for Diabetic Neuropathy       » China Enlists AI to Diagnose Breast Cancer       » Philips and Singapore Institute of Advanced Medicine Holdings Sign Agreement to Open First-of-its-kind Oncology Center in Singapore       » Guardian Partners with MyDoc to Address Singapore's Population Health Needs through Integrating Technology and Self-Care       » Database Boosts Shanghai's Technology Aim      
BIOBOARD For e-subscribers (PDF)
Vol 21, No 04, April 2017
SINGAPORE
NUS Study: Daily Consumption of Tea Protects the Elderly from Cognitive Decline

A cup of tea a day can keep dementia away, and this is especially so for those who are genetically predisposed to the debilitating disease, according to a recent study led by Assistant Professor Feng Lei from the Department of Psychological Medicine at National University of Singapore's (NUS) Yong Loo Lin School of Medicine. The longitudinal study involving 957 Chinese seniors aged 55 years or older has...

Singapore Researchers Use Patients' Stem Cells to Test for Side Effects of Drugs - Discovery Brings Doctors Closer to Personalized Medicine

Different people react differently to the same drug, yet it is difficult to predict the side effects for an individual in advance. Now, researchers from the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR and the National Cancer Centre Singapore (NCCS) have demonstrated a promising approach to screen for severe side effects by first testing the drug on stem cells made from the patient's blood...

UNITED STATES
Diabetes in Your DNA? Scientists Zero in on the Genetic Signature of Risk

ANN ARBOR, Mich. — Why do some people get Type 2 diabetes, while others who live the same lifestyle never do? For decades, scientists have tried to solve this mystery - and have found more than 80 tiny DNA differences that seem to raise the risk of the disease in some people, or protect others from the damagingly high levels of blood sugar that are its hallmark. But no one "Type 2 diabetes signature" has...

Super Resolution Imaging Helps Determine a Stem Cell's Future

Scientists at Rutgers and other universities have created a new way to identify the state and fate of stem cells earlier than previously possible. Understanding a stem cell's fate - the type of cell it will eventually become - and how far along it is in the process of development can help scientists better manipulate cells for stem cell therapy. The beauty of the method is its simplicity and versatility, said...

Wearable Biosensors Can Tell You When to See the Doctor

Your watch might be able to tell you it's time to call in sick. Researchers supported by the National Institutes of Health have revealed the ability of wearable biosensors, similar to the Apple Watch or Fitbit, to detect physiological changes that may indicate illness, even before symptoms appear. The findings, published Jan. 12, 2017, in PLoS Biology, may open the door to new ways to manage and monitor...

AUSTRALIA
PromarkerD Predictive Diagnostics for DKD to Roll-out in Asia

PERTH, AUSTRALIA — Proteomics International Laboratories Ltd, a world leader in biomarker discovery in multiple project areas, was advancing deals in Singapore, Hong Kong and Shanghai for the Asia Pacific commercialization of PromarkerD, the ground-breaking test platform that uses protein biomarkers in the blood to predict the onset of diabetic kidney disease (DKD). Proteomics, or PILL, has been granted...

JAPAN
Enrollment Commences in Phase III Clinical Study of Eisai's BACE Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan

TOKYO — Eisai Co., Ltd. announced on 29th Mar that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) (development code: E2609) in patients with early Alzheimer's disease (AD). The Phase III clinical trial program for elenbecestat (MISSION AD) consists of two global Phase III...

NEWS CRUNCH  
news Vitafoods Asia 2017 heralds a new future of innovation
news Sanner receives Zero Defect Award
news AdAlta pioneers novel drug for rare lung disease
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy